Terns Pharmaceuticals, Inc. (TERN)
$52.95+0.00%Close
BUYBULL · day 42
Key stats
- Market cap
- $4.8B
- Beta
- -0.38
- P/E (TTM)
- -51.41
- 1W
- +0.04%
- 1M
- +0.74%
- vs SPY 1W
- -1.12%
- vs SPY 1M
- -2.25%
Industry peers
FMP comparable companies · ranked by market cap
- RLAYSELLRelay Therapeutics, Inc.$3.9BRECOVERYQ 3$17.88+2.70%
- AMLXSELLAmylyx Pharmaceuticals, Inc.$3.1BCRISISQ 8$28.14+3.46%
- ELVNSELLEnliven Therapeutics, Inc.$2.9BCRISISQ 11$40.98+0.86%
- PGENBUYPrecigen, Inc.$2.8BBULLQ 10$7.81+2.76%
- SNDXSELLSyndax Pharmaceuticals, Inc.$1.5BCRISISQ 17$16.99+0.53%
- INBXSELLInhibrx Biosciences Inc.$1.4BCRISISQ 33$95.01+2.43%
- ORICSELLORIC Pharmaceuticals, Inc.$1.2BBEARQ 3$11.99-0.33%
- TRMLTourmaline Bio, Inc.$1.2B$47.98
- NKTRSELLNektar Therapeutics$1.2BCRISISQ 12$41.17+0.91%
- IMTXSELLImmatics N.V.$996MCRISISQ 6$7.43+0.81%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on TERN?
- LOPJLB’s latest quantitative signal on Terns Pharmaceuticals, Inc. (TERN) is BUY in a BULL regime. Signals are updated daily.
- What market regime is TERN in?
- Terns Pharmaceuticals, Inc. (TERN) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Terns Pharmaceuticals, Inc. (TERN) do?
- Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor…